| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Dihydroarteannuin B is a microbial metabolite of artemisinin B, suggesting that it may share some biological targets with artemisinin and its derivatives. Artemisinin compounds are known to target the malaria parasite through generation of reactive oxygen species and interaction with heme. Dihydroarteannuin B may also have anti-inflammatory activity through inhibition of TNF-α production and NF-κB signaling. However, specific molecular targets have not been fully characterized.
|
|---|---|
| ln Vitro |
In vitro, Dihydroarteannuin B is a microbial metabolite of artemisinin B. It has been reported to ameliorate lupus symptoms in BXSB mice by inhibiting TNF-α production and blocking NF-κB signaling pathway translocation, suggesting anti-inflammatory activity. As a dihydroartemisinin derivative, it may also exhibit antimalarial activity. However, detailed in vitro activity data including IC₅₀ values are not extensively published for this specific compound.
|
| ln Vivo |
In vivo, Dihydroarteannuin B has been reported to ameliorate lupus symptoms in BXSB mice by inhibiting TNF-α production and blocking the NF-κB signaling pathway translocation. This suggests potential anti-inflammatory and immunomodulatory activity. The compound's ability to modulate NF-κB signaling indicates possible therapeutic applications in autoimmune and inflammatory conditions. However, detailed in vivo efficacy data are not extensively published.
|
| Enzyme Assay |
In vitro assays for Dihydroarteannuin B are not extensively documented. As a microbial metabolite of artemisinin B, potential assays could include evaluation of anti-inflammatory activity by measuring TNF-α production in immune cells or NF-κB reporter gene assays. Antimalarial activity could be assessed using Plasmodium falciparum cultures. The compound's structure can be confirmed by NMR and MS.
|
| Cell Assay |
In vitro cellular assays for Dihydroarteannuin B could include evaluation of anti-inflammatory activity in immune cell lines. Cells are treated with the compound and stimulated with LPS or other inflammatory stimuli, and cytokine production (TNF-α, IL-1β, IL-6) is measured by ELISA. NF-κB signaling can be assessed using reporter gene assays or by measuring NF-κB nuclear translocation. Cytotoxicity may be assessed in relevant cell lines using MTT or similar assays.
|
| Animal Protocol |
In vivo animal experiments for Dihydroarteannuin B have been reported in BXSB lupus mice. The compound is administered to mice and endpoints include lupus symptom scores, autoantibody levels, cytokine levels (TNF-α), and NF-κB signaling pathway activity. However, detailed experimental protocols including dosing regimens and administration routes are not extensively published in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Dihydroarteannuin B are characteristic of artemisinin derivatives. The compound has a molecular weight of 250.33 g/mol and molecular formula C₁₅H₂₂O₃. As a lipophilic sesquiterpene, it is expected to have good oral absorption and tissue distribution. Like other artemisinin derivatives, it may undergo metabolism in the liver. Storage: powder at -20°C for 3 years or 4°C for 2 years; in solvent at -80°C for 6 months or -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Dihydroarteannuin B is not extensively documented. As a derivative of artemisinin, which has a well-established safety profile in antimalarial therapy, dihydroarteannuin B is expected to have manageable toxicity. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed.
|
| References |
|
| Additional Infomation |
Reports have indicated that Artemisia annua contains dihydroartemisinin B, and relevant data is available for reference.
Dihydroarteannuin B (CAS# 87206-33-5, molecular formula C₁₅H₂₂O₃, molecular weight 250.33) is a microbial metabolite of artemisinin B from Artemisia annua. It ameliorates lupus symptoms by inhibiting TNF-α production and NF-κB signaling. Also known as (3R)-dihydroarteannuin B. No clinical trials or regulatory approvals have been identified. Storage: powder at -20°C for 3 years. |
| Molecular Formula |
C15H22O3
|
|---|---|
| Molecular Weight |
250.3334
|
| Exact Mass |
250.157
|
| CAS # |
87206-33-5
|
| PubChem CID |
14018832
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.531
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
420
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1[C@]2(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]3([H])[C@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[C@@]4([H])[C@@]([H])(C([H])([H])[H])C(=O)OC34C12[H]
|
| InChi Key |
VWGPQZZLIAQJCE-BRQFDVKVSA-N
|
| InChi Code |
InChI=1S/C15H22O3/c1-8-4-5-11-9(2)12(16)17-15(11)10(8)6-7-14(3)13(15)18-14/h8-11,13H,4-7H2,1-3H3/t8-,9-,10?,11+,13-,14-,15?/m1/s1
|
| Chemical Name |
(4R,5S,8R,12R,14R)-4,8,12-trimethyl-2,13-dioxatetracyclo[7.5.0.01,5.012,14]tetradecan-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9947 mL | 19.9736 mL | 39.9473 mL | |
| 5 mM | 0.7989 mL | 3.9947 mL | 7.9895 mL | |
| 10 mM | 0.3995 mL | 1.9974 mL | 3.9947 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
